Evidence map›Paper›PMID 36190944›Full record

ArticlePloS one2022

The effect of cigarette modified risk claims and brand on perceived risk, product appeal, and use intentions.

Erin Keely O'Brien, Andrea L Ruybal, Amber R Koblitz, Sarah E Johnson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erin Keely O'BrienOffice of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America.ORCID 0000-0002-6208-329X
Andrea L RuybalOffice of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America.ORCID 0000-0003-2610-090X
Amber R KoblitzOffice of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America.
Sarah E JohnsonOffice of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America.
Office of Science · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesNo studies have examined the brand context in which modified risk claims appear on tobacco products. This study examines how marketing products with modified risk claims affects risk perceptions, appeal, and intentions among own-brand, other brand, and novel brand cigarettes.

methodsThis experiment employed a 3 (claim: risk modification [RM], exposure modification [EM], control) x 3 (brand: own, other, novel) between-subjects design. A convenience sample (N = 1,557, Mage = 40.28, SDage = 19.01, 71.3% female, 80.3% White) of current or former Marlboro, Camel, or Newport users was collected. Participants were assigned to view their own brand, another brand, or a novel brand, with or without a claim, and rated perceived risk after switching to this product, product appeal, and use intentions.

resultsParticipants in the RM or EM conditions had lower risk perceptions (versus control). Claim did not affect appeal. Adult established cigarette users in the EM (but not RM) condition had higher intentions (versus control). Participants rated their own and another brand as more appealing than the novel brand. Interactions between brand and claim were not significant.

conclusionsWe found modified risk claims decreased risk perceptions but did not impact appeal. Whereas participants showed preference for their own brand in terms of appeal and intentions, brand did not moderate the impact of claims.

Indexed as

IntentionTobacco ProductsAnimalsFemaleMaleMarketing

Identifiers

PMID36190944
PMCPMC9529086
OpenAlexW4300689238

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.